Recruiting
Phase 3

Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone

Sponsor:

Introgen Therapeutics

Code:

NCT00041626

Conditions

Carcinoma, Squamous Cell

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

INGN 201

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Introgen Therapeutics on 2007-09-11.